ADCLEC.syn1 CAR T / Takeda, Memorial Sloan-Kettering Cancer Center - LARVOL DELTA

Dual-target CAR-T allows researcher to ‘dream big’ about a cure for high-risk leukemia (Healio) - "The first infusion of a phase 1 study using a novel chimeric antigen receptor T-cell therapy for patients with relapsed or refractory acute myeloid leukemia is about to happen and Park could feel his anticipation building...The phase 1 trial is slated to have six patients with relapsed or refractory AML — those with at least one prior line of chemotherapy and who have residual disease. Individuals who have relapsed after bone marrow transplant are also eligible...Study participants will receive lymphodepletion with fludarabine plus cyclophosphamide, and then a single infusion of the CAR T cells....The first six patients will receive a bone marrow biopsy at weeks 2 and 4."

Trial status • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Not yet recruiting ➔ Recruiting | Trial completion date: Feb 2026 ➔ Apr 2028 | Trial primary completion date: Feb 2026 ➔ Apr 2028

CAR T-Cell Therapy • Enrollment open • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2025 ➔ Feb 2026 | Trial primary completion date: Feb 2025 ➔ Feb 2026

CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Cooperative CAR targeting to selectively eliminate AML and minimize escape (Cancer Cell) - "ADCLEC.syn1 prevents antigen escape in AML xenograft models, outperforms the ADGRE2-CAR alone and eradicates AML despite proximate myelopoiesis in humanized mice. Off-target HSPC toxicity is similar to that of a CD19-CAR and can be mitigated by reducing CAR T cell-derived interferon-γ."

Preclinical • Acute Myelogenous Leukemia

A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Initiation date: Jul 2023 ➔ Oct 2023

CAR T-Cell Therapy • Trial initiation date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Memorial Sloan Kettering Cancer Center

CAR T-Cell Therapy • New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology